<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747821</url>
  </required_header>
  <id_info>
    <org_study_id>COV-04-IB</org_study_id>
    <nct_id>NCT04747821</nct_id>
  </id_info>
  <brief_title>An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine</brief_title>
  <acronym>Projeto S</acronym>
  <official_title>A Stepped-wedge Cluster Randomized Trial to Assess the Effectiveness of the Use of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a stepped-wedge cluster randomized trial to assess effectiveness of Sinovac's&#xD;
      Adsorbed COVID-19 (Inactivated) vaccine. Residents in the urban area of a municipality are&#xD;
      eligible to participate. The city was divided in clusters and those cluster were grouped to&#xD;
      determine the offer of vaccination in four steps. The vaccine will be offered to adults (18&#xD;
      years old and above) according to the location of their homes in a cluster. The vaccine&#xD;
      schedule is two doses with four-weeks interval. Baseline samples to determine previous&#xD;
      immunity will be collected before vaccination.&#xD;
&#xD;
      Cases of COVID-19 reported in the city will be recorded according to the WHO clinical&#xD;
      progression scale. Comparison of periods before and after vaccination and relation to&#xD;
      immunization coverage will be considered for the assessment of effectiveness in the clusters&#xD;
      and groups of clusters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">February 17, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Groups of cluster are allocated to offer vaccination in a stepped-wedge mode.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of COVID-19 cases after two-doses immunization schedule in clusters in the first quarter of study</measure>
    <time_frame>Thirteen weeks after the beginning of study vaccination</time_frame>
    <description>Number of virologically-confirmed symptomatic COVID-19 six weeks after beginning of study vaccination up to thirteen weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 cases after two-doses immunization schedule in clusters up to one year of study</measure>
    <time_frame>One year after the beginning of study vaccination</time_frame>
    <description>Number of virologically-confirmed symptomatic COVID-19 six weeks after beginning of study vaccination up to one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization status</measure>
    <time_frame>One year after the beginning of study vaccination</time_frame>
    <description>Number of virologically-confirmed symptomatic COVID-19 six weeks after beginning of study vaccination up to one year according to immunization status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to pre-existing SARS-CoV-2 antibodies</measure>
    <time_frame>One year after the beginning of study vaccination</time_frame>
    <description>Number of virologically-confirmed symptomatic COVID-19 six weeks after beginning of study vaccination up to one year according to pre-existing SARS-CoV-2 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization coverage</measure>
    <time_frame>One year after the beginning of study vaccination</time_frame>
    <description>Number of virologically-confirmed symptomatic COVID-19 six weeks after beginning of study vaccination up to one year according to immunization coverage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalization and death due to COVID-19 after two-doses immunization schedule in clusters</measure>
    <time_frame>One year after the beginning of study vaccination</time_frame>
    <description>Number of hospitalization and death due to COVID-19 six weeks after beginning of study vaccination up to one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average number of reported COVID-19 cases in the study area in comparison to other neighboring cities</measure>
    <time_frame>One year after the beginning of study vaccination</time_frame>
    <description>Average number of reported COVID-19 cases in the microregion where the study area is located</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically-attended adverse reactions to the study vaccine</measure>
    <time_frame>One week after each vaccination</time_frame>
    <description>Number of medically-attended adverse reactions to the study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of severe COVID-19 cases</measure>
    <time_frame>From first vaccination up to one year after first dose</time_frame>
    <description>Frequency of virologically-confirmed severe COVID-19 cases after receiving, at least, one dose of the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events of special interest after immunization</measure>
    <time_frame>From first vaccination up to one year after first dose</time_frame>
    <description>Frequency of adverse events of special interest after receiving, at least, one dose of the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the study vaccine</measure>
    <time_frame>Two weeks after the beginning of study vaccination of the corresponding cluster</time_frame>
    <description>Acceptability rate of the study vaccine in the eligible population of each cluster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to vaccination schedule</measure>
    <time_frame>Six weeks after the beginning of study vaccination of the corresponding cluster</time_frame>
    <description>Adherence rate to vaccination schedule in the population of each cluster</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of SARS-CoV-2 variants in the study area</measure>
    <time_frame>One year after the beginning of study vaccination</time_frame>
    <description>Description of SARS-CoV-2 variants sequenced out of the samples collected in the study area</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>First group of clusters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adsorbed COVID-19 (Inactivated) vaccine offered in the first week of study The vaccine is administrated in two doses with a four-weeks interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second group of clusters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adsorbed COVID-19 (Inactivated) vaccine offered in the second week of study The vaccine is administrated in two doses with a four-weeks interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third group of clusters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adsorbed COVID-19 (Inactivated) vaccine offered in the third week of study The vaccine is administrated in two doses with a four-weeks interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fourth group of clusters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adsorbed COVID-19 (Inactivated) vaccine offered in the fourth week of study The vaccine is administrated in two doses with a four-weeks interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adsorbed COVID-19 (Inactivated) Vaccine</intervention_name>
    <description>Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac</description>
    <arm_group_label>First group of clusters</arm_group_label>
    <arm_group_label>Fourth group of clusters</arm_group_label>
    <arm_group_label>Second group of clusters</arm_group_label>
    <arm_group_label>Third group of clusters</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 years of age or older;&#xD;
&#xD;
          2. Resident in the study area;&#xD;
&#xD;
          3. Show voluntary intention to participate in the study, documented by the informed&#xD;
             consent form signed by participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. For females: Pregnancy (confirmed by positive beta-hCG test), breastfeeding or intent&#xD;
             to engage in sexual relations with reproductive intent without use of birth control&#xD;
             methods in the three months following vaccination;&#xD;
&#xD;
          2. Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease,&#xD;
             according to anamnesis or physical examination. Significant changes in treatment or&#xD;
             hospitalizations due to worsening of the condition in the last three months are&#xD;
             indicators of uncontrolled disease;&#xD;
&#xD;
          3. Diseases with impaired immune system including: neoplasms (except basal cell&#xD;
             carcinoma), congenital or acquired immunodeficiencies and autoimmune diseases not&#xD;
             controlled according to anamnesis or physical examination. Significant changes in&#xD;
             treatment or hospitalizations due to worsening of the condition in the last three&#xD;
             months are indicators of uncontrolled disease;&#xD;
&#xD;
          4. Behavioral, cognitive or psychiatric disease that, in the opinion of the principal&#xD;
             investigator or his or her representative physician, affects the participant's ability&#xD;
             to understand and cooperate with all study protocol requirements;&#xD;
&#xD;
          5. Any alcohol or drug abuse over the 12 months prior to enrollment in the study that has&#xD;
             caused medical, professional or family problems, indicated by clinical history;&#xD;
&#xD;
          6. History of severe allergic reactions or anaphylaxis to the study vaccine or to&#xD;
             components thereof;&#xD;
&#xD;
          7. History of asplenia;&#xD;
&#xD;
          8. Participation in another clinical trial with an investigational product in the six&#xD;
             months prior to enrollment in the study or planned participation in another clinical&#xD;
             trial within the two years following enrollment;&#xD;
&#xD;
          9. Previous participation in a study to evaluate a COVID-19 vaccine or prior exposure to&#xD;
             a COVID-19 vaccine;&#xD;
&#xD;
         10. Use of immunosuppressant therapy regimens within the six months prior to enrollment in&#xD;
             the study for planned use within the two years following enrollment. Immunosuppressant&#xD;
             therapy regimens include: antineoplastic chemotherapy, radiation therapy and&#xD;
             immunosuppressants to induce transplant tolerance, among others.&#xD;
&#xD;
         11. Use of immunosuppressive doses of corticosteroids within the three months prior to the&#xD;
             enrollment in the study and planned use of immunosuppressive doses of corticoids&#xD;
             within the three months following enrollment in the study. Immunosuppressive doses of&#xD;
             corticosteroids will be considered the equivalent prednisone 20 mg/day for adults, for&#xD;
             longer than one week. Continued use of topical or nasal corticosteroids is not&#xD;
             considered an immunosuppressant;&#xD;
&#xD;
         12. Received blood products (transfusions or immunoglobulins) within the three months&#xD;
             prior to enrollment in the study, or planned administration of blood products or&#xD;
             immunoglobulins within the two years following enrollment in the study;&#xD;
&#xD;
         13. Suspected or confirmed fever within the 72 hours prior to vaccination or axillary&#xD;
             temperature greater than 37.8 Â°C* on the day of vaccination (enrollment may be&#xD;
             postponed until participant has gone 72 hours without fever);&#xD;
&#xD;
         14. Possible or confirmed case of COVID-19 on the day of vaccination (vaccination can be&#xD;
             postponed until the participant completes 72 hours without symptoms or the diagnosis&#xD;
             is ruled out);&#xD;
&#xD;
         15. Received live attenuated virus vaccine or inactivated vaccine within the 28 days or 14&#xD;
             days, respectively, prior to enrollment in the study, or immunization planned within&#xD;
             the 28 days after enrollment in the study;&#xD;
&#xD;
         16. History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet&#xD;
             disorder), or prior history of significant bleeding or bruising following IM&#xD;
             injections or venipuncture&#xD;
&#xD;
         17. Any other condition that, in the opinion of the principal investigator or his/her&#xD;
             representative physician, could put the safety/rights of potential participants at&#xD;
             risk or prevent them from complying with this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Butantan Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Estadual de Serrana</name>
      <address>
        <city>Serrana</city>
        <state>SP</state>
        <zip>14150-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 Vaccines</keyword>
  <keyword>Vaccines, Inactivated</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

